Company news
Amplia Therapeutics Ltd. (ASX:ATX) news
Amplia Therapeutics Ltd. news releases on 6ix. Latest, Sep 23, 2024: Sixth Confirmed Response in Pancreatic Cancer Trial
Press releases — page 2
Sixth Confirmed Response in Pancreatic Cancer Trial
September 22, 2024
FDA Fast Track Designation for Narmafotinib
September 19, 2024
Fifth Confirmed Response in ACCENT Trial
August 20, 2024
Amplia Receives R&D Tax Rebate Totalling $3.2 Million
August 11, 2024
Granting of Key Patent in Europe and Japan
August 7, 2024
Additional Patient Response in Pancreatic Cancer Trial
August 5, 2024
Sustained Reduction in Tumour Size Seen In Pancreatic Trial
July 25, 2024
First 26 Patients recruited in Phase 2A ACCENT Trial
July 3, 2024
Preliminary Final Report and Annual Report YE 31 March 2024
May 30, 2024
$4.27m Offer Successfully Completed and ACCENT Trial Update
May 14, 2024
Rights Issue Investor Slide Deck
April 16, 2024
Fully Underwritten 2 for 5 Entitlement Offer to raise $4.27
April 16, 2024
Update on ACCENT Trial in Pancreatic Cancer
March 26, 2024
FDA Clearance Amplia's IND for Pancreatic Cancer Trial in US
January 17, 2024
Amplia Reports First Patient Dosing In Phase 2a Accent Trial
January 16, 2024
Approval to Initiate Phase2 Pancreatic Cancer Trial in Korea
December 3, 2023
Appendix 4D and Financial Report Half Year ended 30 Sep 23
November 20, 2023
Promising Clinical Data 1b ACCENT Trial in Pancreatic Cancer
October 29, 2023
Amplia Receives R&D Tax Rebate Totalling $ 2.4 Million
October 18, 2023
AACR Ovarian Cancer Conference Presentation
October 8, 2023
ATX Quarterly Activities and Cashflow Reports - June 23 Qtr
July 30, 2023
Annual Report to Shareholders
May 30, 2023
AMP945 and FOLFIRINOX active in model of Pancreatic Cancer
May 28, 2023
Grant to collaborate with CSIRO Supplementary Announcement
May 23, 2023
Amplia receives grant to collaborate with CSIRO
May 21, 2023
ACCENT Trial Recruitment Progress
May 9, 2023
Quarterly Activities and Cashflow Reports - March 23 Qtr
April 26, 2023
First Patient Recruited to Cohort 3 of ACCENT Trial
April 18, 2023
Dose Escalation Approved in ACCENT Clinical Trial of AMP945
April 11, 2023
First Patient Recruited to Cohort 2 of Accent Trial
February 1, 2023
Quarterly Activities and Cashflow Reports - December 2022
January 29, 2023
Letter to Shareholders End of Year Summary and 2023 Plans
December 19, 2022
Appendix 4D and Financial Report Half Year ended 30 Sep 22
November 17, 2022
Amplia Appoints Dr Christopher Burns CEO & Managing Director
November 6, 2022
Quarterly Activities and Cashflow Reports - Sep 2022 Qtr
October 27, 2022
AMP886 Activity in Acute Myeloid Leukemia
October 2, 2022
CEO Resignation
September 11, 2022
Amplia Receives $1.8m R&D Tax Incentive
August 30, 2022
CEO & Managing Director Presentation to AGM
August 25, 2022
First Patient Recruited to ACCENT Trial in Pancreatic Cancer
August 2, 2022
Quarterly Activities and Cashflow Reports - June 2022 Qtr
July 28, 2022
AMP945 Shows Efficacy in Model of Lung Fibrosis
June 1, 2022
Preliminary Final Report and Annual Report YE 31 March 2022
May 29, 2022
Amplia Receives Second Ethics Clearance for Phase 2 Trial
May 12, 2022
AMP945 Pre-IND Meeting Outcome
May 8, 2022
Quarterly Activities and Cashflow Reports - March 2022 Qtr
April 19, 2022
Ethics Clearance Phase 2 Trial - Pancreatic Cancer Patients
April 6, 2022
AMP945 Improves Survival in Human Pancreatic Cancer Model
February 16, 2022
Quarterly Activities and Cashflow Reports - Dec 2021 Qtr
January 23, 2022
Amplia Completes Manufacture of AMP945 for Planned Trials
January 12, 2022